Head-to-head evidence
NT-0796 vs VTX3232
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: NLRP3 inflammasome · full Obesity pipeline
NT-0796
Developed by NodThera
NCT07055516 · Phase 2 · completed
The trial was randomized, triple-blind, placebo-controlled, and included 176 participants. Its primary outcomes included the surrogate biomarker hsCRP and change in body weight, but the primary comparison cannot be judged because results have not been posted.
VTX3232
Developed by Zomagen Biosciences and partners
NCT06771115 · Phase 2 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Because the trial’s outcome is currently unknown, the evidence remains limited despite its controlled design.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NT-0796's landscape · VTX3232's landscape